Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Eine sehr spannende aber extrem spekulative Möglichkeit sehe ich aktuell bei Alpine Immune Sciences. Das Unternehmen ist ein Biotech mit einer Marktkapitalisierung von nur 225 Mio. USD und konzentriert sich auf Immuntherapien. Die Aktie konnte am letzten Donnerstag mit einem großen Up-Gap in den Handel starten, als bekannt wurde, dass das Unternehmen eine exklusive weltweite Lizenzvereinbarung...
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index,...
Investing in biotech stocks isnt for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile. However,...
Investing can sometimes require a significant amount of upfront cash. For example, you might need a lot of capital to buy real estate properties or launch a new business....
Vertex Pharmaceuticals $4.9 billion purchase of Alpine Immune Sciences probably wont be the last acquisition of a company focused on kidney disease.
